Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Confidence in New Zealand’s financial markets dips

2018-07-12 nbr.co.nz
Confidence in New Zealand’s financial markets has fallen slightly, with more people uncertain about how effectively the market is regulated.
WYN PPL PUPKY

0
Bloggers, Ardern's baby boost online retail trend

2018-07-06 nzherald.co.nz
The power of "mummy bloggers" and the baby fever sparked by Prime Minister and new mother Jacinda Ardern look set to boost a retail trend - subscription box services for parents.
PPL PUPKY

11
Shares rise after bumpy week, led by NZ Refining

2018-06-22 nzherald.co.nz
New Zealand shares rose, led by New Zealand Refining Company and Synlait Milk while Port of Tauranga and A2 Milk Co fell.
PPL FBU PUPKY MHI FCREY MXRHY NZR FRCEF SKT SYKWF PPSHY FBU SKKTY SML MXRHF

1
ANZ unlikely to see remaining $20m from Pumpkin Patch

2018-06-22 nbr.co.nz
ANZ Bank is unlikely to see all the millions it lent failed childrenswear company Pumpkin Patch, and unsecured creditors probably won’t get a cent.
PPL PUPKY

1
ANZ Bank unlikely to get millions owed to it by failed retailer Pumpkin Patch

2018-06-22 nzherald.co.nz
Failed children's clothing retailer Pumpkin Patch is unlikely to be able to pay back the millions it owes to ANZ Bank while unsecured creditors will get zilch, according to the latest report by the company's receivers KordaMentha.
PPL PUPKY

1
Brian Gaynor: Time to look more closely at corporate failures

2018-06-15 nzherald.co.nz
A major drawback of the New Zealand business sector is the absence of independent analysis of important company issues, including corporate failures.
WYN PPL PUPKY

1
NZX moving in new directions

2018-05-16 nzherald.co.nz
The future of NZ's capital markets lies in building on our economy's unique strengths and recognising the needs of local success stories — not in trying to match what other markets are doing.
PPL MRNRF PUPKY NZSTY NURPF NZSTF NEU

1
Aussie fashion brand enters administration

2018-05-10 ntnews.com.au
A private equity company has bought a majority stake in 90-year-old Australian confectionery maker Darrell Lea. The maker of favourites such as Rocklea Road and liquorice has bounced back following its voluntary administration more than five years ago following a major restructure. Quadrant Private Equity has bought the stake from the Quinn family, which owned the Queensland-based VIP Petfoods, for a reported $200 million.
PPL PUPKY SFH

2
Brian Gaynor: Why the Tegel takeover leaves a bad taste for many investors

2018-05-04 nzherald.co.nz
The total number of main board listings has fallen from 168 to just 155 since the end of 2015. This is the result of more takeovers, receiverships and other delisting decisions, than IPOs.
WYN PPL PUPKY COA SGL GPGPY CGGGF GPGRF LNSTY CGW

1
Esprit to shut all Aussie stores

2018-05-03 ntnews.com.au
FASHION retailer Esprit will close all 67 of its loss-making Australia and New Zealand stores as the Hong Kong-listed company shifts focus to more profitable regions.
PPL PUPKY ESHDF ESPGY SFH 0330

1
Fashion retailer Sambag closes shop after 22 years in business

2018-04-01 theage.com.au
Fashion brand Sambag, known for being worn by A-listers such as Elle Macpherson, is shutting down after 22 years in business.
PPL PUPKY

1
Fashion retailer Sambag closes shop after 22 years in business

2018-04-01 smh.com.au
Fashion brand Sambag, known for being worn by A-listers such as Elle Macpherson, is shutting down after 22 years in business.
PPL PUPKY

9
Stock Takes: Political risk on the rise?

2018-03-22 nzherald.co.nz
Air New Zealand's share price seems to have seen little negative down-side from the political stoush between the company and NZ First MP Shane Jones this week.
PPL PUPKY ANZLY AIR ANZFF ANZFY MEZ AIZ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 745891101